[Evaluation of selected parameters of blood coagulation and fibrinolysis system in patients undergoing total hip replacement surgery with normovolemic hemodilution procedure and standard enoxaparine prophylaxis].
The aim of the study was to evaluate selected blood coagulation and fibrinolysis parameters in patients undergoing total hip replacement surgery with normovolemic hemodilution and standard enoksaparine profilaxis. The study included 66 patients undergoing hip replacement surgery. The group consisted of 51 women and 15 men, within the age range of 47-78, the mean age was 64. In 32 (subgroup II) patients the surgery was performed with the use of normovolemic hemodilution, in 34 (subgroup I) the hemodilution procedure was not applied. The enoksaparine as prophylaxis started 12 hours prior to surgery and continued during hospitalisation. The examination of the coagulation system was performed: on the day of the operation in the morning, on the day of the operation in the evening and on the first day after operation. We determined the concentrations of TAT and PAP complexes, prothrombin fragments 1 + 2 (F1 + 2) and d-dimers (DD).


CONCLUSIONS
1) during total hip replacement surgery and particularly in the period of the first 12 hours after the procedure marked activation of coagulation and fibrinolysis occurRed; 2) the application of the hemodilution procedure does not influence significantly the degree of coagulation and fibrinolysis disorders in the perioperative period, but could reduced incidence of thromboembolic complications in the postoperative period.
Piecuch
Wiesław
W
Oddział Urazowo-Ortopedyczny, SPZOZ w Chełmie.
Sokołowska
Bozena
B
Dmoszyńska
Anna
A
Furmanik
Franciszek
F
D000368:Aged; D000925:Anticoagulants / Q000008:administration & dosage*; D000991:Antithrombins / Q000378:metabolism; D019644:Arthroplasty, Replacement, Hip / Q000009:adverse effects / Q000379:methods*; D001777:Blood Coagulation; D001779:Blood Coagulation Factors / Q000378:metabolism*; D017984:Enoxaparin / Q000008:administration & dosage*; D005260:Female; D005340:Fibrinogen / Q000378:metabolism; D005341:Fibrinolysin / Q000378:metabolism; D005342:Fibrinolysis; D005343:Fibrinolytic Agents / Q000008:administration & dosage*; D006438:Hemodilution; D006801:Humans; D008297:Male; D008875:Middle Aged; D011322:Primary Prevention / Q000379:methods; D011516:Prothrombin / Q000378:metabolism; D013917:Thrombin / Q000378:metabolism; D013923:Thromboembolism / Q000097:blood / Q000209:etiology / Q000517:prevention & control; D013997:Time Factors; D020246:Venous Thrombosis / Q000097:blood / Q000209:etiology / Q000517:prevention & control; D000979:alpha-2-Antiplasmin / Q000378:metabolism
D000925:Anticoagulants; D000991:Antithrombins; D001779:Blood Coagulation Factors; D017984:Enoxaparin; D005343:Fibrinolytic Agents; D000979:alpha-2-Antiplasmin; D011516:Prothrombin; D005340:Fibrinogen; D013917:Thrombin; D005341:Fibrinolysin